Tenax Therapeutics (NASDAQ:TENX) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Tenax Therapeutics (NASDAQ:TENX) released its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.04, FiscalAI reports.

Tenax Therapeutics Stock Performance

Shares of TENX stock traded up $0.04 on Friday, hitting $1.68. The company had a trading volume of 169,004 shares, compared to its average volume of 2,207,277. Tenax Therapeutics has a twelve month low of $1.31 and a twelve month high of $19.40. The firm has a market cap of $62.69 million, a P/E ratio of -1.13 and a beta of 0.99. The stock’s 50-day moving average is $1.82 and its two-hundred day moving average is $9.81.

Analysts Set New Price Targets

Several research firms recently commented on TENX. Guggenheim downgraded shares of Tenax Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, August 31st. Cantor Fitzgerald restated an “overweight” rating on shares of Tenax Therapeutics in a research report on Thursday, September 10th. Wall Street Zen downgraded shares of Tenax Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Leerink Partners set a $4.00 price target on shares of Tenax Therapeutics in a report on Tuesday, August 11th. Finally, UBS Group lowered shares of Tenax Therapeutics to a “neutral” rating in a report on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $14.00.

Insider Activity at Tenax Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc bought 900,000 shares of Tenax Therapeutics stock in a transaction that occurred on Thursday, September 3rd. The shares were acquired at an average cost of $1.78 per share, for a total transaction of $1,602,000.00. Following the completion of the acquisition, the insider directly owned 6,524,151 shares of the company’s stock, valued at approximately $11,612,988.78. The trade was a 16.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders purchased 3,682,899 shares of company stock valued at $6,388,279 over the last quarter. 10.81% of the stock is owned by insiders.

Key Stories Impacting Tenax Therapeutics

Here are the key news stories impacting Tenax Therapeutics this week:

• Positive Sentiment: Tenax reported a third-quarter loss of $0.31 per share, beating the consensus estimate of a $0.35 loss. The company also said analyses of its LEVEL trial informed a predictive-enrichment strategy for the amended LEVEL-2 protocol and that it received an FDA Type C meeting. These developments may support its effort to advance the program, though they do not establish clinical success. Tenax third-quarter results and corporate update
• Negative Sentiment: A securities class action has been filed against Tenax and certain officers on behalf of investors who bought shares from Nov. 13, 2023, through Aug. 7, 2026. The complaint alleges misleading statements about TNX-103’s clinical prospects before the Phase 3 LEVEL trial missed its primary endpoint; these are allegations, not proven findings. The lead-plaintiff deadline is Dec. 28, 2026. Multiple law-firm alerts largely publicize the same case, rather than representing separate lawsuits. Class action filing announcement

About Tenax Therapeutics

Tenax Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and pulmonary diseases. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

Tenax’s lead product candidate is TNX-103, an oral formulation of levosimendan. Levosimendan is a calcium sensitizer and potassium-channel activator that has been approved for certain heart-failure indications outside the United States.